Glenmark Life Sciences Limited (ALIVUS) Stock Statistics & Valuation Metrics

Glenmark Life Sciences Limited has a market cap or net worth of INR 172.84B. The enterprise value is INR 160.21B.

Market Cap

INR 172.84B

Enterprise Value

INR 160.21B

Glenmark Life Sciences Limited has 122,771,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

122,771,450

Owned by Insiders

―

Owned by Institutions

0.44%

Glenmark Life Sciences Limited’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 15.57%.

Return on Equity (ROE)

0.17

Return on Assets (ROA)

0.14

Return on Invested Capital (ROIC)

15.57%

Return on Capital Employed (ROCE)

0.21

Revenue Per Employee

11.23M

Profits Per Employee

2.48M

Employee Count

2,272

Asset Turnover

0.64

Inventory Turnover

2.04

The current PE Ratio of Glenmark Life Sciences Limited is 25.95. Glenmark Life Sciences Limited’s PEG ratio is 1.00.

PE Ratio

25.95

PS Ratio

6.47

PB Ratio

4.79

Price to FCF

117.61

Price to Operating Cash Flow

66.67

PEG Ratio

1.00

In the last 12 months, Glenmark Life Sciences Limited had revenue of 25.52B and earned 5.64B in profits. Earnings per share was 45.99.

Revenue

25.52B

Gross Profit

11.37B

Operating Income

7.22B

Pretax Income

7.51B

Net Income

5.64B

EBITDA

8.32B

Earnings Per Share (EPS)

45.99

In the last 12 months, operating cash flow was 4.33B and capital expenditures -1.94B, giving a free cash flow of 2.39B billion.

Operating Cash Flow

4.33B

Free Cash Flow

2.39B

Free Cash Flow per Share

12.03

Glenmark Life Sciences Limited pays an annual dividend of INR 22.50, resulting in a dividend yield of 0.36%

Dividend Per Share

INR 22.50

Dividend Yield

0.36%

Payout Ratio

N/A

Free Cash Flow Yield

0.85%

Earnings Yield

3.85%

Beta

1.05

52-Week Price Change

54.70%

50-Day Moving Average

1358.53

200-Day Moving Average

1129.44

Relative Strength Index (RSI)

61.76

Average Volume (3m)

15.89K

Glenmark Life Sciences Limited upcoming earnings date is Jan 28, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Jan 28, 2027

Ex-Dividend Date

Oct 17, 2023

Glenmark Life Sciences Limited as a current ratio of 5.21, with Debt / Equity ratio of 1.70%

Current Ratio

5.21

Quick Ratio

3.85

Debt to Market Cap

0.00

Net Debt to EBITDA

0.07

Interest Coverage Ratio

134.39

In the past 12 months, Glenmark Life Sciences Limited has paid 1.87B in taxes.

Income Tax

1.87B

Effective Tax Rate

0.25

Glenmark Life Sciences Limited EV to EBITDA ratio is 18.03, with an EV/FCF ratio of 117.79.

EV to Sales

6.48

EV to EBITDA

18.03

EV to Free Cash Flow

117.79

EV to Operating Cash Flow

66.75

Glenmark Life Sciences Limited has INR 6.53B in cash and marketable securities with INR 1.13B in debt, giving a net cash position of INR 5.39B billion.

Cash & Marketable Securities

INR 6.53B

Total Debt

INR 1.13B

Net Cash

INR 5.39B

Net Cash Per Share

INR 43.94

Tangible Book Value Per Share

INR 244.19

Gross margin is 50.89%, with operating margin of 31.31%, and net profit margin of 24.95%.

Gross Margin

50.89%

Operating Margin

31.31%

Pretax Margin

33.09%

Net Profit Margin

24.95%

EBITDA Margin

35.96%

EBIT Margin

32.46%

The average price target for Glenmark Life Sciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

8.19%

EPS Growth Forecast

26.12%

Smart Score

―

AI Score

76.6